Glaxo 2nd-Quarter Lucre Up 1.4 Per Centum

"We proceed to see very good advancement crossways the rest of our portfolio" GlaxoSmithKline PLC, whose shares have been weighed down by a negative study on its megahit diabetes drug Avandia, reported Wednesday that net net rose 1.4 percent in the 2nd quarter, even as revenue fell.The world's second-largest pharmaceutical troupe reported net earnings of 1.33 1000000000000 pounds ($2.75 billion) compared to 1.32 a billion pounds in the same time period a year ago.Revenue dropped 2.4 percentage to 5.67 one million million pounds ($11.7 billion).Pretax net was literally unaltered at 1.9 one million million pounds, drubbing the market consensus for a little drop. Read more